Jamie Lim

St Thomas' Hospital — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index2.9kcitations51works3.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Single-cell and spatial transcriptomics(14), Cancer Genomics and Diagnostics(10), Ovarian cancer diagnosis and treatment(6), Immune Cell Function and Interaction(5), Neuroinflammation and Neurodegeneration Mechanisms(5)

Publications49 total

#1532 Effectiveness & cost-effectiveness of post-discharge transitional care programmes for fluid overload readmissions amongst chronic kidney disease patients in Singapore
Nephrology Dialysis Transplantation·2025Open Access
Proteomic analysis uncovers biological diversity in molecularly defined endometrial carcinomas
Neoplasia·2025Open Access
Lymphoproliferative Disorders Mimicking Rheumatologic Disease: A Clinical Reasoning Perspective
Current Allergy and Asthma Reports·2025
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer
Nature·2025· 18 citedOpen Access
Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction
Nature Communications·2025· 10 citedOpen Access
Histopathological Analysis Of High Grade Serous Ovarian Cancer (HGSOC) Using Artificial Intelligence Quantified Tumour Stroma Proportion (TSP)
International Journal of Gynecological Cancer·2025
Single Cell RNA Sequencing Of The Tumour Microenvironment Characterises Malignant Epithelial And Cancer-Associated Fibroblasts In HGSOC
International Journal of Gynecological Cancer·2025
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
iScience·2024· 2 citedOpen Access
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome
Science Translational Medicine·2024· 11 citedOpen Access
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
2024Open Access
ARGX-119, a therapeutic agonist antibody targeting MuSK
2024· 1 citedOpen Access
Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer
2024· 10 citedOpen Access
A Quality and Completeness Assessment of Testicular Cancer Health Information on TikTok
Société Internationale d’Urologie Journal·2024Open Access
Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK
Scientific Reports·2023· 10 citedOpen Access
Ovarian cancer mutational processes drive site-specific immune evasion
Nature·2022· 261 citedOpen Access
EP299/#232 Genomic instability as a determinant of immune escape in ovarian cancer
E-Posters·2022Open Access
Single-cell genomic variation induced by mutational processes in cancer
Nature·2022· 143 citedOpen Access
Enhanced Capabilities Through Automated Machine Learning Characterization of Natural Gas Powered Assets
2022
Abstract 2553: Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes
Cancer Research·2022· 1 cited
Abstract 5795: Validation of FDA approved oncoReveal Dx lung and colon cancer assay (oRDx-LCCA)
Cancer Research·2022
page 1 of 3Next →

Frequent Co-authors

Sohrab P. Shah(20), Allen W. Zhang(13), Andrew McPherson(12), Nicholas Ceglia(11), Daniel Lai(11), Samuel Aparício(11), Jessica N. McAlpine(10), Ciara H. O’Flanagan(8), Kieran R. Campbell(8), Dawn R. Cochrane(8), Diljot Grewal(8), David G. Huntsman(8), Florian Uhlitz(8), Britta Weigelt(8), Dmitriy Zamarin(8), Tyler Funnell(7), Ignacio Vázquez-Garćıa(7), Eliyahu Havasov(7), Nicole Rusk(7), Marc Williams(7)